Results from the randomized, controlled ADAURA trial, which evaluated the EGFR tyrosine kinase inhibitor osimertinib versus placebo in the adjuvant setting for patients with stage IB-IIIA EGFR mutation-positive non-small cell lung cancer were first presented at the 2020 ASCO Annual Meeting and published online ahead of print in the New England Journal of Medicine (2020; doi: 10.1056/NEJMoa2027071). The data revealed osimertinib indeed improved disease-free survival significantly, stirring much enthusiasm.